Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pirfenidone to Reduce Radiation Lung Injury in Lung Cancer Patients
NCT05801133Phase 2Completed
- Sponsor
- Hubei Cancer Hospital
- Start
- Mar 2023
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pirfenidone in radiation pneumonitis (RP), sponsored by Hubei Cancer Hospital. Started Mar 2023; status: completed.
02
Drugs
pirfenidone
03
Conditions
radiation pneumonitis (RP)
Beyond the preview
Go deeper on NCT05801133.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05801133.